Literature DB >> 26306063

Risk Factors, Pattern and Clinical Outcome of Acute Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Stem Cell Transplant.

Alok Gupta1, Sachin Punatar1, Jayant Gawande1, Libin Mathew1, Bhausaheb Bagal1, Sadhana Kannan2, Navin Khattry1.   

Abstract

We sought to determine risk factors, pattern and outcome of acute graft versus host disease (aGVHD) in seventy-seven acute leukemia patients who underwent allogeneic stem cell transplant at our centre from January 2008 to March 2013. GVHD prophylaxis with cyclosporine-methotrexate or cyclosporine-mycophenolate mofetil was used. Patients were divided in 2 groups, grade II-IV aGVHD (group A) and grade 0-I aGVHD (group B). Incidence of any grade and grade II-IV aGVHD was 44 and 18 %, respectively. The most common site of aGVHD was gastro-intestinal tract (65 %) followed by skin (35 %). Higher total nucleated cell (TNC) dose infused was associated with increased incidence of grade II-IV aGVHD. Incidence of relapse and incidence of slippage of chimerism was 21 and 36 % in group A while 37 and 27 % in group B respectively. Transplant related mortality (TRM) was 21 % in group A and 13 % in group B. Probability of OS and RFS at 4 years was 63 and 34 % in group A compared with 40 and 38 % in group B, respectively. We conclude that higher TNC dose infused is a risk factor for grade II-IV aGVHD with gut being the commonest site. Grade II-IV aGVHD did not have a significant impact on incidence of relapse, TRM and OS.

Entities:  

Keywords:  Acute graft-versus-host disease; Acute leukemia; Allogeneic stem cell transplantation; GVHD prophylaxis; Transplant outcome

Year:  2015        PMID: 26306063      PMCID: PMC4542763          DOI: 10.1007/s12288-014-0499-5

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  40 in total

1.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

Authors:  Madan Jagasia; Mukta Arora; Mary E D Flowers; Nelson J Chao; Philip L McCarthy; Corey S Cutler; Alvaro Urbano-Ispizua; Steven Z Pavletic; Michael D Haagenson; Mei-Jie Zhang; Joseph H Antin; Brian J Bolwell; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Robert Peter Gale; Vikas Gupta; Stephanie J Lee; Mark Litzow; Daniel J Weisdorf; Mary M Horowitz; Theresa Hahn
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

2.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

Authors:  J M Goldman; R P Gale; M M Horowitz; J C Biggs; R E Champlin; E Gluckman; R G Hoffmann; S J Jacobsen; A M Marmont; P B McGlave
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

3.  Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 x 10(9)/l neutrophils on 3 consecutive days to define myeloid recovery.

Authors:  M Y Ali; Y Oyama; J Monreal; J Winter; M Tallman; L I Gordon; S Williams; S Singhal; J Mehta
Journal:  Bone Marrow Transplant       Date:  2002-12       Impact factor: 5.483

4.  Risk factors for acute graft-versus-host disease.

Authors:  R P Gale; M M Bortin; D W van Bekkum; J C Biggs; K A Dicke; E Gluckman; R A Good; R G Hoffmann; H E Kay; J H Kersey
Journal:  Br J Haematol       Date:  1987-12       Impact factor: 6.998

5.  Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  R E Champlin; N Schmitz; M M Horowitz; B Chapuis; R Chopra; J J Cornelissen; R P Gale; J M Goldman; F R Loberiza; B Hertenstein; J P Klein; E Montserrat; M J Zhang; O Ringdén; S C Tomany; P A Rowlings; M E Van Hoef; A Gratwohl
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

6.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

Authors:  Marco Mielcarek; Paul J Martin; Wendy Leisenring; Mary E D Flowers; David G Maloney; Brenda M Sandmaier; Michael B Maris; Rainer Storb
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

7.  Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.

Authors:  Theresa Hahn; Philip L McCarthy; Mei-Jie Zhang; Dan Wang; Mukta Arora; Haydar Frangoul; Robert Peter Gale; Gregory A Hale; John Horan; Luis Isola; Richard T Maziarz; Jon J van Rood; Vikas Gupta; Joerg Halter; Vijay Reddy; Pierre Tiberghien; Mark Litzow; Claudio Anasetti; Stephen Pavletic; Olle Ringdén
Journal:  J Clin Oncol       Date:  2008-11-03       Impact factor: 44.544

8.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

Review 9.  Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Mohamad Mohty; Béatrice Gaugler
Journal:  Cytokine Growth Factor Rev       Date:  2007-12-20       Impact factor: 7.638

10.  Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.

Authors:  Irene García Cadenas; David Valcarcel; Rodrigo Martino; J L Piñana; Pere Barba; Silvana Novelli; Albert Esquirol; Ana Garrido; Silvana Saavedra; Miquel Granell; Carol Moreno; Javier Briones; Salut Brunet; Jorge Sierra
Journal:  Mediators Inflamm       Date:  2014-01-30       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.